Company
OBI Pharma, Inc.
Headquarters: Taipei, Taiwan
CEO: Dr. Michael N. Chang PH.D.
Market Cap
TW$8.74 Billion
TWD as of July 1, 2025
US$298.6 Million
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
OBI Pharma, Inc., a bio-pharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor carbohydrate antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immuno-oncology drug; OBI-888, a passive immunotherapy monoclonal antibody designed for targeting Globo H; OBI-999, an antibody drug conjugate; OBI-898 SSEA4, a passive immunity monoclonal antibody; OBI-998 SSEA4, an antibody small molecule drug complex, which targets toxic drugs to malignant tumors; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a clostridium botulinum toxin. The company was founded in 2002 and is based in Taipei, Taiwan.
Stocks & Indices
OBI Pharma, Inc. has the following listings and related stock indices.
Stock: TWSE: 4174 wb_incandescent